Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical compositions of drugs and neutralized acidic polymers

a technology of neutralized acid and pharmaceutical compositions, applied in the field of pharmaceutical compositions of drugs and neutralized acidic polymers, can solve the problems of drug and/or dispersion not being physically stable, drug and/or dispersion may not be chemically stable within some dispersion polymers, and continue to present challenges in the distribution of low-solubility drugs in polymers, etc., to achieve superior concentration enhancement and improve the chemical stability of acid-sensitive drugs

Inactive Publication Date: 2003-03-20
BEND RES
View PDF20 Cites 82 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0025] In another preferred embodiment, the composition provides improved chemical stability of said drug relative to a second control composition, wherein said second control composition comprises a dispersion of an equivalent quantity of said low-solubility drug and an unneutralized form of said neutralized acidic enteric polymer. Preferably, the composition provides a relative degree of improvement in stability for said drug of at least 1.25, preferably at least 3, more preferably at least 10, when stored at 40.degree. C. and 75% relative humidity.
[1298] Generally, it is preferred that the dispersion of drug be formulated for long-term storage in the dry state as this promotes the chemical and physical stability of the drug.

Problems solved by technology

Nevertheless, dispersing a low-solubility drug in a polymer continues to present challenges.
One problem encountered is that the drug and / or dispersion may not be physically stable.
The inventors have also found that for some drugs, the drugs are not chemically stable within some dispersion polymers.
In particular, the inventors have observed that for dispersions containing certain drugs and acidic polymers, the drug chemically degrades in the dispersion over time, resulting in a loss of potency and an increase in unwanted impurities.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical compositions of drugs and neutralized acidic polymers
  • Pharmaceutical compositions of drugs and neutralized acidic polymers
  • Pharmaceutical compositions of drugs and neutralized acidic polymers

Examples

Experimental program
Comparison scheme
Effect test

examples 1-3

[1311] These examples disclose dispersions of a drug and a neutralized acidic polymer. For Examples 1-3, a dispersion of the acid-sensitive drug quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1(S)-3-fluorobenzyl)-2(S), 7-dihydroxy-7-methyl-octyl] amide (Drug 1) and the neutralized acidic enteric polymer hydroxypropyl methyl cellulose acetate succinate (HPMCAS) was made by first preparing a solution containing drug, polymer and a base. For Example 1, the solution consisted of 1.25 wt % Drug 1, 0.513 wt % sodium acetate, and 3.75 wt % HPMCAS-HF (HF grade of HPMCAS from Shin Etsu, Tokyo, Japan) in methanol / water (9 / 1). For Example 2, the solution consisted of 1.25 wt % Drug 1, 0.32 wt % sodium bicarbonate, and 3.75 wt % HPMCAS-HF in methanol / water (9 / 1). For Example 3, the solution consisted of 1.25 wt % Drug 1, 1.42 wt % sodium borate, and 3.75 wt % HPMCAS-HF in methanol / water (9 / 1). For control Cl, the solution consisted of 1.25 wt % Drug 1 and 3.75 wt % HPMCAS-HF, with no added base....

example 4

[1313] Stability of the acid-sensitive drug in the dispersions of Examples 1-3 was determined by measuring the drug purity before and after storage for Examples 1-3 and control C1. Dispersions were stored under elevated temperature and humidity conditions to increase the rate of chemical and physical changes occurring in the materials in order to simulate a longer storage interval in a typical storage environment. Drug purity was determined using HPLC. A Kromasil C.sub.4 HPLC column was used with a mobile phase of 45 vol % of 0.2 vol % H.sub.3PO.sub.4, and 55 vol % acetonitrile. UV detection was measured at 245 nm. Drug 1 potency was the percent of the total HPLC peak area corresponding to the amount of drug originally present in the dispersion prior to storage. Results of potency analysis of dispersions of Drug 1 and neutralized HPMCAS after storage for five days at 40.degree. C. / 75% RH are shown in Table 2.

2TABLE 2 Aqueous- Drug 1 Potency Degree of Soluble Conc. In the Day 5 at De...

examples 5-6

[1315] These examples disclose dispersions of Drug 1 and an acidic polymer with different degrees of neutralization. Amorphous solid dispersions of Drug 1 and HPMCAS were made by first mixing Drug 1 in a solvent together with HPMCAS-MF and sodium hydroxide to form a solution. For Example 5, the solution comprised 0.29 wt % Drug 1, 0.89 wt % HPMCAS-MF, 0.038 wt % NaOH, and 98.782 wt % water / acetonitrile (9 / 1). (MF grade of HPMCAS available from Shin Etsu, Tokyo, Japan) The percentage of acidic groups on the polymer that were neutralized was approximately 99%. For Example 6, the solution comprised 0.31 wt % Drug 1, 0.94 wt % HPMCAS-MF, 0.019 wt % NaOH, and 98.731 wt % water / acetonitrile (9 / 1). The percent age of acidic groups on the polymer that were neutralized was approximately 50%. For Control C2, the solution comprised 0.33 wt % Drug 1 and 1.00 wt % HPMCAS-MF in 98.67 wt % water / acetonitrile (9 / 1). The solutions of Examples 5 and 6, and Control C2, were lyophilized to remove the s...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
glass transition temperatureaaaaaaaaaa
wt %aaaaaaaaaa
solubilityaaaaaaaaaa
Login to View More

Abstract

Pharmaceutical compositions comprised of low-solubility and / or acid-sensitive drugs and neutralized acidic polymers are disclosed.

Description

[0001] This application claims the benefit of priority of provisional Patent Application Serial No. 60 / 300,256 filed Jun. 22, 2001, which is incorporated herein in its entirety for all purposes.[0002] This invention relates to pharmaceutical compositions of drugs and neutralized acidic polymers that provide improved chemical and physical properties.[0003] It is often desired to improve the aqueous concentration and bioavailability of a poorly soluble drug. Improving either the dissolution rate of the drug or the maximum concentration of drug achieved in an aqueous use environment can enhance the absorption and hence bioavailability of the drug. Further, decreasing the rate at which the concentration of drug falls from the maximum concentration to the equilibrium concentration may also improve bioavailability.[0004] Forming a dispersion of a drug and polymer may enhance drug concentration in a use environment. For example, Curatolo, et al., EP 0 901 786 A2 disclose forming pharmaceut...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/14C07D215/46A61K9/16A61K9/20A61K31/404A61K31/405A61K31/4706A61K31/496A61K31/498A61K47/32A61K47/38A61P3/06A61P43/00
CPCA61K9/143A61K9/145A61K31/717A61K31/7024A61K31/498A61K31/496A61K31/4745A61K31/4706A61K31/4439A61K31/405A61K31/404A61K31/00A61K9/1652A61K9/146A61K9/1611A61K2300/00A61P3/06A61P43/00A61K47/30
Inventor CREW, MARSHALL D.FRIESEN, DWAYNE T.KETNER, RODNEY J.SHANKER, RAVI M.WEST, JAMES B.
Owner BEND RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com